Post-polypectomy surveillance interval and advanced neoplasia detection rates: a multicenter, retrospective cohort study.


Journal

Endoscopy
ISSN: 1438-8812
Titre abrégé: Endoscopy
Pays: Germany
ID NLM: 0215166

Informations de publication

Date de publication:
10 2022
Historique:
pubmed: 12 4 2022
medline: 28 9 2022
entrez: 11 4 2022
Statut: ppublish

Résumé

Longer post-polypectomy surveillance intervals are associated with increased colorectal neoplasia detection at surveillance in some studies. We investigated this association to inform optimal surveillance intervals. Patients who underwent colonoscopy and post-polypectomy surveillance at 17 UK hospitals were classified as low/high risk by baseline findings. We compared detection rates of advanced adenomas (≥ 10 mm, tubulovillous/villous, high grade dysplasia), high risk findings (HRFs: ≥ 2 serrated polyps/[adenomas] of which ≥ 1 is ≥ 10 mm or has [high grade] dysplasia; ≥ 5 serrated polyps/adenomas; or ≥ 1 nonpedunculated polyp ≥ 20 mm), or colorectal cancer (CRC) at surveillance colonoscopy by surveillance interval (< 18 months, 2, 3, 4, 5, 6 years). Risk ratios (RRs) were estimated using multivariable regression. Of 11 214 patients, 7216 (64 %) were low risk and 3998 (36 %) were high risk. Among low risk patients, advanced adenoma, HRF, and CRC detection rates at first surveillance were 7.8 %, 3.7 %, and 1.1 %, respectively. Advanced adenoma detection increased with increasing surveillance interval, reaching 9.8 % with a 6-year interval ( Metachronous neoplasia was uncommon among low risk patients, even with long surveillance intervals, supporting recommendations for no surveillance in these patients. For high risk patients, a 3-year surveillance interval would ensure timely CRC detection.

Sections du résumé

BACKGROUND
Longer post-polypectomy surveillance intervals are associated with increased colorectal neoplasia detection at surveillance in some studies. We investigated this association to inform optimal surveillance intervals.
METHODS
Patients who underwent colonoscopy and post-polypectomy surveillance at 17 UK hospitals were classified as low/high risk by baseline findings. We compared detection rates of advanced adenomas (≥ 10 mm, tubulovillous/villous, high grade dysplasia), high risk findings (HRFs: ≥ 2 serrated polyps/[adenomas] of which ≥ 1 is ≥ 10 mm or has [high grade] dysplasia; ≥ 5 serrated polyps/adenomas; or ≥ 1 nonpedunculated polyp ≥ 20 mm), or colorectal cancer (CRC) at surveillance colonoscopy by surveillance interval (< 18 months, 2, 3, 4, 5, 6 years). Risk ratios (RRs) were estimated using multivariable regression.
RESULTS
Of 11 214 patients, 7216 (64 %) were low risk and 3998 (36 %) were high risk. Among low risk patients, advanced adenoma, HRF, and CRC detection rates at first surveillance were 7.8 %, 3.7 %, and 1.1 %, respectively. Advanced adenoma detection increased with increasing surveillance interval, reaching 9.8 % with a 6-year interval (
CONCLUSIONS
Metachronous neoplasia was uncommon among low risk patients, even with long surveillance intervals, supporting recommendations for no surveillance in these patients. For high risk patients, a 3-year surveillance interval would ensure timely CRC detection.

Identifiants

pubmed: 35405762
doi: 10.1055/a-1795-4673
pmc: PMC9500009
doi:

Types de publication

Clinical Trial Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

948-958

Informations de copyright

The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).

Déclaration de conflit d'intérêts

AJC, as Chief Investigator, was the recipient of all the funding. MDR reports personal fees from Swiss SCWeb AG, Pentax, and Norgine, and a grant from Olympus, outside the submitted work. All other authors declare no competing interests.

Références

Gut. 2020 Sep;69(9):1645-1658
pubmed: 31953252
Intest Res. 2017 Jan;15(1):109-117
pubmed: 28239321
Dig Endosc. 2020 May;32(4):503-511
pubmed: 31242329
Endoscopy. 2016 Nov;48(11):995-1002
pubmed: 27485482
Lancet Oncol. 2017 Jun;18(6):823-834
pubmed: 28457708
Endoscopy. 2020 Aug;52(8):687-700
pubmed: 32572858
Gastrointest Endosc. 2020 Mar;91(3):463-485.e5
pubmed: 32044106
Health Technol Assess. 2017 Apr;21(25):1-536
pubmed: 28621643
Endoscopy. 2012 Sep;44 Suppl 3:SE151-63
pubmed: 23012119
Gut. 2020 Feb;69(2):201-223
pubmed: 31776230
Clin Gastroenterol Hepatol. 2009 Jan;7(1):86-92
pubmed: 18829395
Gut. 2002 Oct;51 Suppl 5:V6-9
pubmed: 12221031
Endoscopy. 2013 Oct;45(10):842-51
pubmed: 24030244
Gut. 2017 Jul;66(7):1181-1196
pubmed: 28450390
N Engl J Med. 1993 Apr 1;328(13):901-6
pubmed: 8446136
Gut. 2011 Nov;60(11):1537-43
pubmed: 21427200
Gut. 2021 Dec;70(12):2307-2320
pubmed: 33674342

Auteurs

Amanda J Cross (AJ)

Cancer Screening and Prevention Research Group (CSPRG), Department of Surgery and Cancer, Imperial College London, London, United Kingdom.

Emma C Robbins (EC)

Cancer Screening and Prevention Research Group (CSPRG), Department of Surgery and Cancer, Imperial College London, London, United Kingdom.

Kevin Pack (K)

Cancer Screening and Prevention Research Group (CSPRG), Department of Surgery and Cancer, Imperial College London, London, United Kingdom.

Iain Stenson (I)

Cancer Screening and Prevention Research Group (CSPRG), Department of Surgery and Cancer, Imperial College London, London, United Kingdom.

Matthew D Rutter (MD)

Department of Gastroenterology, University Hospital of North Tees, Stockton-on-Tees, United Kingdom.
Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne, United Kingdom.

Andrew M Veitch (AM)

Department of Gastroenterology, New Cross Hospital, Wolverhampton, United Kingdom.

Brian P Saunders (BP)

Wolfson Unit for Endoscopy, St Mark's Hospital, London, United Kingdom.

Stephen W Duffy (SW)

Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University, London, United Kingdom.

Kate Wooldrage (K)

Cancer Screening and Prevention Research Group (CSPRG), Department of Surgery and Cancer, Imperial College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH